Staff turnover in EUR2,516,6323,276,4507,337,09020,645,404744,831
Staff turnover in EUR2,516,6323,276,4507,337,09020,645,404744,831
The share: stated in EUR20212022202320242025
Shares outstanding (in mn.)3.283.663.6839.412.56
Dividend per share-----
Basic earnings per share-0.23-0.43-0.38-0.120.06
P/L in EUR million under IAS/IFRS20212022202320242025
Turnover13.818.033.675.6121.3
Operating income (EBIT)-9.6-14.7-14.4-3.54.9
Earnings before taxes-9.6-16.0-13.3-3.34.2
Annual net profit/ loss-7.5-14.6-13.7-3.72.0
Balance sheet in EUR million under IAS/IFRS20212022202320242025
Assets
Total current assets32.931.427.244.865.5
Total fixed assets63.456.648.743.541.7
Total assets96.388.075.988.3107.2
Liabilities
Total short-term liabilities11.312.613.220.933.4
Total long-term liabilities8.16.66.08.66.9
Total provisions0.40.00.00.10.0
Equity capital77.068.956.758.766.9
Total liabilities96.388.075.988.3107.2
Management:
Chris Fair
Florence Barrère de Groot
Katherine Sage
Philippe Saudan
Joost de Bruijn
Daniel Geiger
G. Joseph Ross
John Griffin
Laura Rosa
Marcel Borger
Sjoerd Musters
Board:
Joost de Bruijn
Kimberley Elting
Oliver Walker
Clemens van Blitterswijk
Shareholding in %:
BlackRock Fund Advisors 0.98
BlackRock Investment Management (UK) Ltd. 1.80
C A C M Oomen 24.74
Deka Investment GmbH 1.88
Janus Henderson Investors UK Ltd. 1.16
Joh. Berenberg, Gossler & Co. KG (Investment Management) 2.25
Pegasus Global Opportunity Fund Ltd. 2.70
UBS Asset Management Switzerland AG 2.69
Universal-Investment-Gesellschaft mbH (Invt Mgmt) 2.97
Zürcher Kantonalbank (Investment Management) 1.67
Freefloat 57.17
Address: Wagistrasse 25, 8952 Schlieren
T: +41-44-733-47-47
F: +41-44-733-47-40
I: http://kurosbio.com
E: [email protected]